Total Payments
$34,201
2024 Payments
$1,400
Companies
49
Transactions
568
Medicare Patients
649
Medicare Billing
$110,269
Payment Breakdown by Category
Research$20,875 (61.0%)
Food & Beverage$10,418 (30.5%)
Consulting$1,800 (5.3%)
Education$701.27 (2.1%)
Other$350.00 (1.0%)
Travel$55.96 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,875 | 2 | 61.0% |
| Food and Beverage | $10,418 | 550 | 30.5% |
| Consulting Fee | $1,800 | 1 | 5.3% |
| Education | $701.27 | 13 | 2.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $350.00 | 1 | 1.0% |
| Travel and Lodging | $55.96 | 1 | 0.2% |
Payments by Type
Research
$20,875
2 transactions
General
$13,326
566 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $20,875 | 2 | $0 (2021) |
| Genentech USA, Inc. | $1,975 | 128 | $0 (2024) |
| Heron Therapeutics, Inc. | $1,974 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $950.91 | 57 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $924.21 | 39 | $0 (2024) |
| Merck Sharp & Dohme LLC | $703.28 | 42 | $0 (2024) |
| Celgene Corporation | $693.47 | 35 | $0 (2024) |
| Amgen Inc. | $654.82 | 26 | $0 (2024) |
| Incyte Corporation | $541.48 | 21 | $0 (2024) |
| GENZYME CORPORATION | $469.09 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,400 | 54 | AstraZeneca Pharmaceuticals LP ($267.54) |
| 2023 | $1,319 | 54 | AstraZeneca Pharmaceuticals LP ($226.63) |
| 2022 | $1,527 | 73 | Genentech USA, Inc. ($267.06) |
| 2021 | $21,878 | 50 | Eli Lilly and Company ($20,875) |
| 2020 | $993.03 | 36 | GENZYME CORPORATION ($350.00) |
| 2019 | $1,587 | 94 | Genentech USA, Inc. ($499.45) |
| 2018 | $1,683 | 91 | Genentech USA, Inc. ($362.04) |
| 2017 | $3,814 | 116 | Heron Therapeutics, Inc. ($1,974) |
All Payment Transactions
568 individual payment records from CMS Open Payments — Page 3 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/19/2024 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: BioOncology | ||||||
| 01/16/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.11 | General |
| Category: Hematology | ||||||
| 01/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $30.59 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $25.62 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.05 | General |
| Category: Oncology | ||||||
| 12/20/2023 | Genentech USA, Inc. | Alecensa (Biological), Rozlytrek, Tecentriq | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: BioOncology | ||||||
| 12/14/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $125.10 | General |
| Category: Oncology | ||||||
| 12/12/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.34 | General |
| Category: Oncology | ||||||
| 11/28/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Foundation Medicine, Inc. | FOUNDATIONONE LIQUID CDX | Food and Beverage | In-kind items and services | $28.33 | General |
| 11/09/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.81 | General |
| 11/08/2023 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: HEMATOLOGY | ||||||
| 10/19/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Oncology | ||||||
| 10/17/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: ONCOLOGY | ||||||
| 09/28/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.89 | General |
| Category: Oncology | ||||||
| 09/26/2023 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $33.36 | General |
| Category: BioOncology | ||||||
| 09/21/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.45 | General |
| 09/19/2023 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | Cash or cash equivalent | $20.29 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Incyte Corporation | — | Education | Cash or cash equivalent | $65.00 | General |
| 09/12/2023 | ImmunoGen, Inc. | Elahere (Biological) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Oncology | ||||||
| 09/06/2023 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $19.21 | General |
| 08/31/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $29.97 | General |
| Category: Oncology | ||||||
| 08/24/2023 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Genetically Defined Disease | ||||||
| 08/22/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Oncology | ||||||
| 08/10/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $20,875 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 119 | 204 | $94,980 | $23,149 |
| 2022 | 5 | 160 | 282 | $92,351 | $28,522 |
| 2021 | 5 | 163 | 240 | $66,045 | $26,853 |
| 2020 | 5 | 207 | 327 | $89,082 | $31,745 |
Total Patients
649
Total Services
1,053
Medicare Billing
$110,269
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 39 | 88 | $50,349 | $10,003 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 43 | $24,556 | $6,436 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $9,045 | $2,923 | 32.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 22 | $5,049 | $2,110 | 41.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 15 | $2,407 | $868.40 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 15 | 16 | $3,574 | $808.87 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 40 | 93 | $42,663 | $10,683 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 65 | $14,676 | $5,559 | 37.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 25 | $11,113 | $4,054 | 36.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 48 | $10,521 | $3,255 | 30.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 21 | $8,626 | $3,251 | 37.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 30 | $4,752 | $1,720 | 36.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 56 | 107 | $30,959 | $12,581 | 40.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 55 | $12,120 | $4,840 | 39.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 29 | $12,600 | $4,791 | 38.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 16 | $4,636 | $2,412 | 52.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 14 | $3,003 | $1,182 | 39.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 19 | $2,727 | $1,047 | 38.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 61 | 116 | $33,234 | $10,075 | 30.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 41 | 49 | $21,144 | $8,494 | 40.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 43 | 87 | $19,075 | $7,756 | 40.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 32 | 38 | $8,094 | $2,209 | 27.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 14 | $4,011 | $1,770 | 44.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 23 | $3,525 | $1,441 | 40.9% |
About Dr. Paramjeet Khosla, M.D
Dr. Paramjeet Khosla, M.D is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376527523.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paramjeet Khosla, M.D has received a total of $34,201 in payments from pharmaceutical and medical device companies, with $1,400 received in 2024. These payments were reported across 568 transactions from 49 companies. The most common payment nature is "" ($20,875).
As a Medicare-enrolled provider, Khosla has provided services to 649 Medicare beneficiaries, totaling 1,053 services with total Medicare billing of $110,269. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/01/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1376527523
Products in Payments
- CINVANTI (Drug) $1,974
- OPDIVO (Biological) $647.42
- KEYTRUDA (Biological) $546.38
- Alecensa (Biological) $528.02
- ELITEK (Biological) $350.00
- TECENTRIQ (Biological) $340.50
- Perjeta (Biological) $267.48
- VERZENIO (Drug) $261.41
- Avastin (Biological) $238.49
- IMFINZI (Biological) $225.18
- ERLEADA (Drug) $216.93
- Cabometyx (Drug) $215.82
- GAZYVA (Biological) $199.46
- ZEJULA (Drug) $191.34
- KISQALI (Drug) $187.03
- Pomalyst (Drug) $184.89
- Kadcyla (Biological) $179.76
- JAKAFI (Drug) $177.38
- CALQUENCE (Drug) $169.64
- IBRANCE (Drug) $153.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678